Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367299 | 0.80 | PTPN11 (0.46) | ERAP2ERAP1LNPEPRAB9APTPN11 | |
| SCHEMBL5359229 | 0.79 | CDC25B (0.44) | ERAP2ERAP1LNPEPMEN1NPC1 | |
| SCHEMBL5359079 | 0.79 | ERAP2 (0.42) | ERAP2ERAP1LNPEPRAB9APTPN11 | |
| SCHEMBL5361041 | 0.77 | FNTA (0.47) | ERAP2ERAP1LNPEPNPC1RAB9A | |
| SCHEMBL5374055 | 0.76 | AOC3 (0.47) | RARBPLA2G4B | |
| SCHEMBL4209446 | 0.76 | ERAP2 (0.42) | ERAP2ERAP1LNPEPRAB9APTPN11 | |
| SCHEMBL1750827 | 0.76 | HPGDS (0.41) | ERAP2ERAP1LNPEPNPC1RAB9A | |
| SCHEMBL5360954 | 0.75 | ALOX15 (0.42) | ERAP2ERAP1LNPEPMEN1RAB9A | |
| SCHEMBL5360875 | 0.74 | PTPN11 (0.44) | ERAP2ERAP1LNPEPMEN1KMT2A | |
| SCHEMBL4227732 | 0.74 | ERAP2 (0.40) | ERAP2ERAP1LNPEPPTPN11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | claimed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | claimed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | claimed |
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | disclosed |
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | disclosed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | MITF, AHR, PAH | ERAP2 3377/4885ERAP1 4598/4885LNPEP 4085/4885 |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | ERAP2 2594/4885ERAP1 3415/4885LNPEP 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.